Human recombinant interferon alpha-2a inhibits angiogenesis of chick area vasculosa in shell-less culture.
In vivo suppression of neovascularization by in situ administration of human recombinant interferon alpha 2a (hrIFN-alpha 2a) was tested on the chick embryo area vasculosa (AV). Methylcellulose discs, each containing 5 IU of hrIFN-alpha 2a were implanted onto the AV at Hamburger-Hamilton (HH) stage 13, and inhibition of blood vessel growth was morphometrically evaluated between HH stages 20 and 27. Our results show: (i) a decreased extent of the AV; (ii) a decreased AV total vessel length; (iii) modified percent ratios of different classes of AV vessels having a definite length. The observed effects of treating with hrIFN-alpha 2a are likely attributable to inhibition of endothelial cell proliferation.
Ribatti
D
D
Institute of Human Anatomy, Histology and Embryology, University of Bari, Italy.
Vacca
A
A
Iurlaro
M
M
Ria
R
R
Roncali
L
L
Dammacco
F
F
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001808:Blood Vessels / Q000187:drug effects / Q000196:embryology*; D002455:Cell Division; D002642:Chick Embryo / Q000098:blood supply*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000196:embryology; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000494:pharmacology*; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins